IL1B and systemic-onset juvenile idiopathic arthritis: Canakinumab has been found to be highly effective in the treatment of sJIA as it binds selectively to IL-1β, inactivates IL-1β signaling pathways, and neutralizes its downstream effects [1, 11–15].